H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences on Monday, setting a price target of $50, which is approximately 329.18% above the present share price of $11.65.
Trucchio expects ATAI Life Sciences to post earnings per share (EPS) of -$0.21 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in ATAI Life Sciences, with an average price target of $31.33.
The analysts price targets range from a high of $50 to a low of $17.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $266 thousand and a net profit of -$33.36 million. The company's market cap is $1.87 billion.
According to TipRanks.com, H.C. Wainwright analyst Patrick Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.9% and a 33.33% success rate.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.